Class Action Notice for Intellia Therapeutics, Inc. (NASDAQ: NTLA)
The Gross Law Firm is reaching out to shareholders of Intellia Therapeutics, Inc. concerning a recently filed class action. This important notice aims to inform all relevant shareholders about their rights and any potential recovery opportunities related to the company's recent developments.
Details for Shareholders
Investors who acquired shares of NTLA within the specified class period are urged to contact the firm. The appointment as lead plaintiff is not mandatory for shareholders wishing to partake in any recovery options, which is a encouraging note for those affected.
Class Period Information
The class period runs from July 30, 2024, to January 8, 2025. This timeframe is crucial for determining eligibility and potential recovery related to the shares purchased during this period.
Allegations Against Defendants
According to the allegations in the complaint, defendants provided misleading information about Intellia's Phase 1/2 study of NTLA-3001 targeting alpha-1 antitrypsin deficiency (AATD)-linked lung disease. The company projected confidence in its timelines, stating that dosing of the first patient would occur in the latter half of 2024.
However, it has come to light that there was a significant decline in demand for viral-based editing as scientific research gravitated toward more effective non-viral delivery methods. This misalignment has rendered NTLA-3001 an unsustainable project for Intellia.
Impact of the Company’s Announcement
The situation worsened on January 9, 2025, when Intellia released a statement regarding a major company reorganization. Though the specifics may vary, it has been disclosed that all research associated with NTLA-3001 would be halted and that a workforce reduction of 27% would take place in 2025, posing severe implications for existing and potential investors.
This revelation led to a noticeable decline in the stock price, which dropped from $12.02 per share on January 8, 2025, to $10.20 per share just two days later. This resounding impact has affected many investors who are now contemplating their next steps.
Deadline for Action
April 14, 2025, is the critical deadline for shareholders to engage in this class action. It is essential for those impacted to register their information and seek potential recovery solutions.
Next Steps for Shareholders
After registration, shareholders are enrolled in a portfolio monitoring software that will grant updates throughout the entire lifecycle of the case. Importantly, the process to seek lead plaintiff status must also be completed by the April deadline.
Why Choose The Gross Law Firm?
The Gross Law Firm stands as a premier advocate for investors facing risks due to deception, fraud, and unlawful business maneuvers. The firm is dedicated to promoting accountability within the business landscape and stands firmly in support of investors who have suffered losses due to misleading statements.
Contact Information
For more details, connect with The Gross Law Firm located at 15 West 38th Street, 12th floor, New York, NY 10018. Shareholders can also reach the firm at (646) 453-8903. The path to seeking justice does not require notable fees or obligations at this stage.
Frequently Asked Questions
What is the class action about?
The class action involves allegations against Intellia Therapeutics regarding misleading statements about their research program for NTLA-3001 that led to significant losses for investors.
Who can participate in the class action?
Shareholders who purchased NTLA shares during the specified class period from July 30, 2024, to January 8, 2025, can participate in the class action.
What are the deadlines I need to be aware of?
The critical deadline to register for the class action is April 14, 2025. It is important to act promptly to ensure eligibility.
Will I need to pay any fees to participate?
There are no fees or upfront costs for shareholders to participate in this case. Registration does not obligate you to significant financial commitments.
What happens after I register?
After registration, shareholders will receive updates through a monitoring system regarding the status of the case and any developments in the proceedings.
